Published in Medical Letter on the CDC and FDA, October 10th, 2004
Berlex Laboratories, Schering's U.S. affiliate, is seeking approval for the use of Bonefos as an adjuvant oral treatment for reducing the occurrence of bone metastases in stage II/III breast cancer patients.
"We are tremendously pleased that the FDA has accepted Bonefos for priority review," said Reinhard von Roemeling, MD, VP Clinical Development Oncology, Schering AG Group. "This designation recognizes the significant unmet medical need facing women currently living with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.